Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Editas Medicine, Inc. (EDIT)
Price$3.23Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M | $90.7M | $20.5M | $31.9M | $13.7M | $6.1M | $1.6M | — |
| Research & development | $90.0M | $199.2M | $177.7M | $175.0M | $142.5M | $158.0M | $96.9M | $90.7M | $83.2M | $57.0M | $18.8M | $5.1M |
| Operating expenses | $200.5M | $283.5M | $247.3M | $245.7M | $218.7M | $225.6M | $161.5M | $145.7M | $133.7M | $103.2M | $36.9M | $12.7M |
| Operating income | −$160.0M | −$251.2M | −$169.2M | −$225.9M | −$193.1M | −$134.8M | −$140.9M | −$113.7M | −$119.9M | −$97.2M | −$35.3M | −$12.7M |
| Operating margin | −394.89% | −777.22% | −216.56% | −1,146.26% | −756.13% | −148.61% | −686.39% | −356.10% | −873.64% | −1,605.62% | −2,167.71% | — |
| EBITDA | −$154.7M | −$245.3M | −$163.1M | −$219.6M | −$188.1M | −$130.9M | −$138.1M | −$110.5M | −$117.3M | −$96.0M | −$34.8M | −$12.6M |
| EBITDA margin | −381.87% | −759.25% | −208.80% | −1,114.11% | −736.35% | −144.25% | −672.60% | −345.91% | −854.09% | −1,585.76% | −2,138.80% | — |
| Net income | −$160.1M | −$237.1M | −$153.2M | −$220.4M | −$192.5M | −$116.0M | −$133.7M | −$110.0M | −$120.3M | −$97.2M | −$72.9M | −$13.7M |
| Net profit margin | −395.01% | −733.72% | −196.13% | −1,118.26% | −753.61% | −127.82% | −651.43% | −344.28% | −876.49% | −1,605.53% | −4,475.14% | — |
| Basic EPSper basic share | -$1.80 | -$2.88 | -$2.02 | -$3.21 | -$2.85 | -$1.98 | -$2.68 | -$2.33 | -$2.98 | -$3.02 | -$28.55 | -$12.46 |
| Diluted EPSper diluted share | -$1.80 | -$2.88 | -$2.02 | -$3.21 | -$2.85 | -$1.98 | -$2.68 | -$2.33 | -$2.98 | -$3.02 | -$28.55 | -$12.46 |
Owners
Reported shareholders
11.35%of listed shares
TCG Crossover Management, LLC11.11M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
TCG Crossover Management, LLC | 11.35%11.11M shares |
BlackRock, Inc. | 10.82%10.59M shares |
RA CAPITAL MANAGEMENT, L.P. | 9.08%8.89M shares |
Commodore Capital LP | 9.08%8.89M shares |
ADAR1 Capital Management, LLC | 9.08%8.89M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 6.28%6.14M shares |
Paradigm Biocapital Advisors LP | 5.71%5.59M shares |
Opaleye Management Inc. | 3.95%3.86M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.68%3.6M shares |
Woodline Partners LP | 3.63%3.56M shares |
Vivo Capital, LLC | 3.63%3.56M shares |
GordonMD Global Investments LP | 3.20%3.13M shares |
GOLDMAN SACHS GROUP INC | 2.67%2.61M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.63%2.57M shares |
RENAISSANCE TECHNOLOGIES LLC | 2.52%2.47M shares |
Logos Global Management LP | 2.27%2.22M shares |
STATE STREET CORP | 2.24%2.19M shares |
MARSHALL WACE, LLP | 2.08%2.04M shares |
D. E. Shaw & Co., Inc. | 1.94%1.9M shares |
JPMORGAN CHASE & CO | 1.90%1.86M shares |
Percentages use 97.87M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 3, 2026Form 4 · 10b5-1 | Parison AmySVP, Chief Financial Officer | SellCommon Stock | 464 | $2.70 | $1.3K | 15.0K |
| Jun 3, 2026Form 4 · 10b5-1 | O'Neill Gilmore NeilCEO | SellCommon Stock | 15.4K | $2.70 | $41.5K | 248.3K |
| Jun 3, 2026Form 4 · 10b5-1 | Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER | SellCommon Stock | 731 | $2.70 | $2.0K | 67.3K |
| Mar 3, 2026Form 4 · 10b5-1 | O'Neill Gilmore NeilCEO | SellCommon Stock | 5.4K | $2.02 | $10.9K | 263.7K |
| Mar 3, 2026Form 4 · 10b5-1 | Parison AmySVP, Chief Financial Officer | SellCommon Stock | 474 | $2.02 | $957.48 | 15.4K |